期刊
QUALITY OF LIFE RESEARCH
卷 28, 期 1, 页码 253-265出版社
SPRINGER
DOI: 10.1007/s11136-018-2000-7
关键词
Symptoms; Hemodialysis; Content validity; Concept elicitation; Cognitive debriefing interview; End-stage kidney disease; Patient-reported outcome measure
类别
资金
- Renal Research Institute (RRI), a subsidiary of Fresenius Medical Care (FMC), North America [A17-1082]
- National Institute of Diabetes and Digestive and Kidney Diseases of the National Institute of Health [K23 DK109401]
PurposeTo describe the process and preliminary qualitative development of a new symptom-based patient-reported outcome measure (PROM) intended to assess hemodialysis treatment-related physical symptoms.MethodsExperienced interviewers conducted concept elicitation and cognitive debriefing interviews with individuals receiving in-center hemodialysis in the United States. Concept elicitation interviews involved eliciting spontaneous reports of symptom experiences and probing to further explore and confirm concepts. We used patient-reported concepts to generate a preliminary symptom PROM. We conducted 3 rounds of cognitive debriefing interviews to evaluate symptom relevance, item interpretability, and draft item structure. We iteratively refined the measure based on cognitive interview findings.ResultsForty-two adults receiving in-center hemodialysis participated in the concept elicitation interviews. A total of 12 symptoms were reported by >10% of interviewees. We developed a 13-item initial draft instrument for testing in 3 rounds of cognitive interviews with an additional 52 hemodialysis patients. Participant responses and feedback during cognitive interviews led to changes in symptom descriptions, division of the single item nausea/vomiting into 2 distinct items, removal of daily activity interference items, addition of instructions, and clarification about the recall period, among other changes.ConclusionsSymptom Monitoring on Renal Replacement Therapy-Hemodialysis (SMaRRT-HD) is a 14-item PROM intended for use in hemodialysis patents. SMaRRT-HD uses a single treatment recall period and a 5-point Likert scale to assess symptom severity. Qualitative interview data provide evidence of its content validity. SMaRRT-HD is undergoing additional testing to assess measurement properties and inform measure scoring.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据